This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Clovis Oncology: Pancreatic Cancer Drug Fails Late-Stage Test

BOULDER, Colo. ( TheStreet) -- Clovis Oncology (CLVS) is shutting down development of its experimental pancreatic cancer drug C0-101 following negative results from a late-stage study, the company said Monday.

Pancreatic cancer patients treated with CO-101 did not live any longer than patients treated with the chemotherapy drug gemcitabine. Median survival in each arm of the study was approximately six months.

"We are obviously disappointed with these results, which are unambiguous," said Clovis CEO Pat Mahaffy.

Clovis shares closed Friday at $21.49.

[<b>Celgene</b> <span class=" TICKERFLAT">(<a href="/quote/CELG.html">CELG</a> - <a href=";ticker=CELG">Get Report</a><a class=" arrow" href="/quote/CELG.html"><span class=" tickerChange" id="story_CELG"></span></a>)</span> reported Friday a positive survival benefit from a <a href="">phase III study of its cancer drug Abraxane in pancreatic cancer</a>.]

Clovis' CO-101 is novel, lipid-conjugated form of gemcitabine developed to benefit pancreatic cancer patients with low levels of of a protein known as hENT1. Previous research suggested low hENT1 levels prevented ordinary gemcitabine from getting into pancreatic tumor cells. CO-101 was designed to enter pancreatic cancer cells independently of a patient's hENT1 status. Once inside the cell, CO-101 was converted to the active form of gemcitabine.

But Monday, Clovis acknowledged that hENT1 status had no impact on survival for pancreatic cancer patients on gemcitabine.

Clovis has two other cancer drugs in early stages of clinical studies. The company anticipates ending the year with approximately $140 million in cash.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CELG $100.90 0.00%
CLVS $13.19 0.00%
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs